Market news
PureTech Health PLC (PTCHF) ended H1 2026 with $220 million in cash, cut go-forward burn to $30--$40 million annually, and is running ahead of its target of three concept-stage programs per year.
PureTech Health (NASDAQ:PRTC) outlined progress across its portfolio in its 2026 half-year results call, highlighting external financings for Celea Therapeutics and Seaport Therapeutics, regulatory progress at Gallop Oncology, and a strategy centered on earlier external funding for its founded entit
PureTech Health plc (LSE:PRTC) said it will publish its results for the six months ended 30 June 2026 on Tuesday, 22 September 2026. The company will hold a presentation and conference call at 9:00 a.
PureTech Health’s (LSE:PRTC) founded entity, Celea Therapeutics, has enrolled the first patient in SURPASS-IPF, a global Phase 3 clinical trial designed to compare its investigational therapy, deupirfenidone, directly against the approved treatment pirfenidone in patients with idiopathic pulmonary fibrosis (IPF). The randomized study will follow around 1,100 participants over a 52-week period and is the first industry-sponsored Phase 3 IPF trial to evaluate two active therapies without a placebo
BOSTON, July 13, 2026--PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of IPF
This is the newest page. Registered accounts read further back.